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1. Introduction 
The enzyme-linked immunosorbent assay (ELISA) has been the cornerstone of in vitro protein 
diagnostics for over 40 years, and remains critical throughout healthcare for the detection and 
quantification of disease biomarkers in clinical samples [1]. However, the emergence of 
personalized and stratified medicine with their inherent requirement for multiplexed, high-
throughput diagnostics, together with the ease-of-use and low cost requirements imposed by the 
drive towards point-of-care diagnostics are changing the landscape. Innovative diagnostic devices 
are essential for realizing these emerging trends.  
 
Label-free affinity biosensors are widely considered to be the technological solution to address 
these challenges. These analytical devices consist of a highly specific, high affinity probe 
molecule, most commonly an antibody, that is immobilized on the surface of a physiochemical 
transducer. The transducer monitors any binding event directly, i.e. without the need for an 
additional antibody, enzymatic, fluorescent or radioactive label, or any other amplification method, 
to provide a response that is proportional to the concentration of bound molecules. Possibly the 
best known biosensor of this type is the surface plasmon resonance (SPR) sensor for monitoring 
of antibody-antigen interactions [2]. SPR exploits the high sensitivity of surface plasmons to 
refractive index changes close to a metal surface, which leads to a change in resonance angle or 
wavelength. A local change in refractive index, for example due to the binding of an antigen to an 
antibody immobilized on the metal surface, can thus be detected in real-time and label-free by the 
corresponding shift in resonance. Today, SPR is a well-established biophysical technique that 
underpins fundamental research across the biological and biomedical sciences. SPR is however 
rarely used in clinical diagnostics, mainly due to high instrument and sensor costs. Current 
biosensor research is therefore focused on alternative technologies that can provide highly 
sensitive and selective protein detection but on a platform that is easy to use, low cost and 
amenable for use in the clinic, at point-of-care or even in the home. Innovative biosensor research 
is flourishing; 2898 articles with ‘biosensor’ in the title were published in 2015 compared to 504 in 
2000 (data from Web of Science). Much of the research to date has focused on the development 
and optimization of transducer materials, including a recent emphasis on carbon-based biosensors 
[3,4], and physiochemical transduction strategies, with transducers that are sensitive to the optical, 
electrochemical and mechanical properties of biological molecules receiving most attention. A 
number of comprehensive review articles have been published that focus on biosensor 
transduction strategies [5-7]. There is also a significant body of work on optimized surface 
chemistries for antibody immobilization and alternative high-affinity binding agents such as 
antibody fragments, DNA and peptide aptamers, and molecularly imprinted polymers [8]. This 
editorial provides an overview of two major trends of biosensor research, namely the move 
towards high-density biosensor arrays and the development of multi-modal biosensor 
technologies.  
 
2. The fabrication of high-density biosensor arrays for multiplexed diagnostics 
A comprehensive understanding of complex biological processes, both in health and disease, will 
require high-throughput quantification of molecular expression profiles, ideally in a single test. This 
multiplexed approached to protein monitoring is not only critical for fundamental biomedical 
research, but also underpins strategies for personalized medicine and the discovery of novel 
disease biomarkers. The multiplexed detection of tens, hundreds or even thousands of protein 
species in a small clinical sample is a significant technological challenge that requires new 
technological solutions. To this end, many types of photonic and electrochemical biosensors 
already use the low-cost, yet high volume and high precision mass-manufacturing techniques 
developed by the semiconductor industry that is capable of producing biosensors with a sub-
micrometer footprint, ideal for high-density integration. Unfortunately, the biochemical 
functionalisation technology required to place different probe molecules onto each sensor does not 
offer the same level of integration. For example, dot-printing approaches for creating antibody 
arrays are currently spatially limited to around 0.1 mm. Although the resolution of these printing 
techniques is likely to improve, the feature sizes required for high-density biosensor arrays capable 
of handling extremely small sample volumes are likely to remain beyond the scope of such 
systems. While high spatial resolution molecular immobilization has been demonstrated in the 
laboratory, for example using nanografting [9] or dip-pen nanolithography [10], these serial 
approaches do not provide the high-throughput required for mass-fabrication of high-density 
protein arrays.  
 
Electrochemically controlled functionalization is a promising approach to spatially direct the 
immobilization of biomolecules, that simultaneously meets the requirements of resolution, speed, 
and the ability to coat each biosensor within an array with a different probe molecule. For example, 
electrochemical cleavage of the gold-thiol bond has been used to direct the immobilization of 
different proteins onto 20 µm diameter metallic electrodes separated by 15 µm [11]. The electrode 
microarray was subsequently used to demonstrate label-free, electronic detection of cyclin-
dependent protein kinases in whole-cell lysates, with no measurable cross-talk between 
functionalized electrodes. A similar spatial resolution (1 µm) was also demonstrated using 
electrochemical grafting of diazonium salts onto conductive surfaces [12]. The use of diazonium 
salts is applicable to a wide variety of conductive surfaces, including silicon, and has recently been 
exploited to create a label-free, silicon photonic biosensor array with the potential for highly-
multiplexed molecular detection [13]. These studies demonstrate the great potential of 
electrochemically-directed approaches for site-selective functionalization. Further research will 
determine the ultimate spatial resolution achievable and explore the limits of functionalization 
across a high-density array in terms of speed, specificity and efficiency and whether this is 
sufficient for production at a scale viable for commercialization. 
 
3. Multi-modal, label-free biosensors. 
The majority of existing label-free biosensors are single mode; detection is provided by a 
transducer sensitive to single physiochemical property. For example, the formation of an antibody-
antigen complex is detected in SPR by measuring the corresponding change in refractive index, 
while capacitive biosensors detect the change in impedance of an antibody layer upon antigen 
binding. Biosensors that combine multiple transduction mechanisms are becoming increasing 
popular. Such truly multi-modal assays can simultaneously probe multiple biomolecular properties, 
e.g. in the optical, electronic and/or chemical domains to provide greater insight and broaden the 
range of systems accessible for analysis. A prominent example of such multi-modal biosensing is 
electrochemical SPR (EC-SPR), where the gold surface that supports the optical mode is also 
used as the working electrode in an electrochemical cell. The complementary information 
contained in both the electrochemical and optical domains not only provides deeper insight into the 
biomolecular processes occurring at surfaces, but has also been used to improve biosensor 
accuracy. For example, a glucose biosensor based on an EC-SPR has been demonstrated in 
which the simultaneous electrochemical and optical measurements were combined to differentiate 
between the enzymatic activity of glucose oxidase and the unwanted background of non-enzymatic 
reactions [14]. Novel insights into enzymatic activity have also been reported using a multi-modal 
biosensor that combines electrochemical measurements with quartz crystal microbalance (QCM), 
which is sensitive to changes in both the mass and viscoelasticity of an immobilized molecular 
layer [15].  
 
Ideally, one would like to combine the best of both worlds, i.e. multiplexing large arrays of sensors 
on a tiny surface area capable of profiling biomarker content in a small sample volume, with each 
sensing region performing multiple types of analysis. So far, this is not possible: existing 
microarrays can perform many tests in parallel, but they require a relatively large volume due to 
their macoscopic size; SPR and QCMD can perform multimodal analysis, but only on a single or a 
very small number of spots. We believe that the route towards true multimodal multiplexed 
detection is silicon technology. To this end, the electrophotonic silicon biosensor combines 
photonic and electrochemical detection in a single, microfabricated biosensor array. The ability to 
combine electrochemical and optical detection in silicon was achieved by controlling the doping 
density profile of a silicon photonic microring resonator such that the dopants were located in a thin 
layer at the silicon surface. The doped surface layer can thus be optimized to be sufficiently 
conductive to support electrochemical processes while thin enough to minimize losses of the 
optical mode confined within the resonant structure. The same platform can also be used to 
electrochemically direct the immobilization of probe molecules, thereby achieving both multimodal 
and highly multiplexed detection. 
 
4. Conclusions and outlook 
Changes in approaches to healthcare require a new generation of diagnostics that are able to 
detect large numbers of proteins simultaneously, with high sensitivity and selectivity, and in a 
platform that is simple, cheap and portable enabling tests to be performed in clinic, at point-of-care, 
or even in the home. Label-free affinity biosensors are an emerging technology with the potential to 
meet these requirements and significant progress has been made, especially by exploiting the 
technological advances of the silicon microelectronics industry. While the translation of this new 
diagnostic technology and associated biomarkers into clinical practice still pose a number of 
technical, scientific and regulatory challenges, the opportunities to transform healthcare practice 
and patient outcomes are substantial.  
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